The landscape of tumor biology, particularly in high-grade gliomas, has been expanded through integrative approaches combining proteomic, metabolomic, and genomic analyses. A study involving 228 tumors revealed that despite the well-documented genomic anomalies in glioblastoma, the 5-year survival rate remains critically low. The research identified heterogeneous upstream alterations that converge on common downstream events, emphasizing the complexity of tumor evolution and the need for multi-scale regulatory interactions in understanding glioma pathogenesis (ref: Liu doi.org/10.1016/j.ccell.2024.06.004/). In the realm of treatment strategies, the efficacy of newer-generation tyrosine kinase inhibitors (TKIs) for non-small cell lung cancer (NSCLC) was evaluated, showing that patients treated with CNS-penetrant TKIs, with or without upfront stereotactic radiosurgery (SRS), had varying outcomes in terms of CNS progression and overall survival (ref: Pike doi.org/10.1200/JCO.23.02668/). Additionally, the localization of protoporphyrin IX during glioma-resection surgery was enhanced through advanced microscopy techniques, improving the detection of tumor cells during surgery (ref: Nasir-Moin doi.org/10.1038/s41551-024-01217-3/). Contradictory findings emerged regarding the prognostic roles of age and tumor grade in astrocytoma versus oligodendroglioma, indicating a need for tailored surgical strategies based on tumor type (ref: van der Vaart doi.org/10.1158/1078-0432.CCR-24-0901/). Lastly, the study of medulloblastoma stem cell programs highlighted the role of OTX2 in alternative splicing, suggesting potential therapeutic targets in pediatric brain tumors (ref: Saulnier doi.org/10.1038/s41556-024-01460-5/).